Form 4 for RLAY Relay Therapeutics, Inc.

Accepted 2026-07-02 16:12:40 ET · period of report 2026-06-30 · accession 0001193125-26-294528 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
T	2026-07-02 16:12	2026-06-30	RLAY	Rahmer Peter	See remarks	S - Sale	$19.09	-50.0K	225.9K	-18%	-$954.5K
T	2026-07-02 16:12	2026-06-30	RLAY	Rahmer Peter	See remarks	A - Grant	$6.95	+3,056	228.9K	+1%	+$21.2K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-06-30	S	D	50,000	$19.09	225,857	D	—	—	(F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 31, 2025. (F2) This transaction was executed in multiple trades at prices ranging from $18.66 to $19.78. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F3) Includes 9,153 shares underlying restricted stock units.
2	Common	Common Stock	2026-06-30	A	A	3,056	$6.95	228,913	D	—	—	(F4) The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction. (F5) In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on January 2, 2026. (F3) Includes 9,153 shares underlying restricted stock units.